---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-26-000012"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:28:41.354064+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# EBS Q4 net loss $1.04/sh, FY2025 net income $0.93/sh; FY2026 rev guidance $720-760M

## Summary
- Full year 2025 total revenues $742.9M, down 29% from $1,043.6M in 2024.
- Q4 2025 net loss $54.6M ($1.04 loss per diluted share), vs Q4 2024 loss $31.3M.
- Full year 2025 net income $52.6M ($0.93 diluted EPS), vs prior year net loss $190.6M.
- Adjusted EBITDA for FY2025 $205.0M, up 12% from $183.1M in 2024.
- FY2026 guidance: revenues $720-760M, adjusted net income $25-45M, adjusted EBITDA $135-155M.

## SEC filing metadata
- accession: 0001367644-26-000012
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000012/0001367644-26-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000012/ebs-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-26-000012
- JSON: https://secwatch.observer/filing/0001367644-26-000012.json
- Plain text: https://secwatch.observer/filing/0001367644-26-000012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.